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We evaluated the performance of the molecular lab-on-chip-based VerePLEX Biosystem for detection of multidrug-resistant
tuberculosis (MDR-TB), obtaining a diagnostic accuracy of more than 97.8% compared to sequencing andMTBDRplus assay for
Mycobacterium tuberculosis complex and rifampin and isoniazid resistance detection on clinical isolates and smear-positive
specimens. The speed, user-friendly interface, and versatility make it suitable for routine laboratory use.
Multidrug-resistant tuberculosis (MDR-TB) requires longand expensive treatment and often results in poor clinical
outcome in both low- and high-income countries (1, 2). The
World Health Organization (WHO) has endorsed specific molec-
ular diagnostics to improve fast diagnosis of MDR-TB (3–5).
However, the genotypic diversity and geographical distribution of
Mycobacterium tuberculosis complex (MTBC), together with the
inability to provide appropriate interpretation of silent mutations
and the limited versatility are some of the restraints undermining
the effectiveness of the current tools on a global scale (6–13).
In the present study, we evaluated a lab-on-chip (LoC) de-
vice, developed by STMicroelectronics (Geneva, Switzerland)
and marketed by Veredus Laboratories (Republic of Singa-
pore) as the VerePLEX Biosystem, for the diagnosis of
MDR-TB and detection of common nontuberculous mycobac-
teria (NTM). The molecular assay was evaluated on both clin-
ical isolates and direct specimens in low- and high-burden set-
tings.
We tested 91 MTBC isolates (see Table S1 in the supplemental
material) harboring different patterns of mutations in rpoB, katG,
and inhA genes to evaluate the probes on the array listed in Table
1. Eighty respiratory specimens positive for acid-fast bacilli by
smear microscopy and MTBC culture positive were decontami-
nated according to international guidelines and included in the
study (Table S1) (14). An additional 116 MTBC culture-negative
specimens were included in the analysis. DNA from isolates and
specimens was extracted by thermal lysis and sonication as de-
scribed elsewhere (15). Phenotypic drug susceptibility testing
(DST) for rifampin (RIF) and isoniazid (INH) was performed
according to international recommendations (16). Some of the
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TABLE 1 Probes spotted onto the array and targeted mycobacterial
species and MDR-TB targets included in the assay
Targeted mycobacterial species or
MDR-TB target Probe(s)
TargetedMycobacterium species
M. avium MYC4a
M. intracellulare MYC5a
M. simiae,M. kansasii,M. scrofulaceum MYC6a
M. abscessus,M. chelonae MYC8a
M. xenopi MYC17a
M. haemophylum MYC19a
M. fortuitum MYC31a
M. tuberculosis complex MYC15a-MYC16a
MDR-TB targets
rpoB
WT codons 510 to 513 L511_w3a
L511P mutant L511P_m3
WT codons 515 to 518 D516_w5
D516V mutant D516V_m1
WT codons 523 to 526 H526_w14
H526D mutant H526D_m2
H526Y mutant H526Y_m5
WT codons 530 to 533 S531L_w1
S531L mutant S531L_m2
katG
WT codons 313 to 317 S315_w2
S315T1 mutant S315T1_m2
S315T2 mutant S315T2_m1
inhA
WT nucleotides21 to7 inhA_w3
T-8A mutant InhA–8TA_m2
T-8C mutant InhA–8TC_m2
C-15T mutant InhA–15CT_m3
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specimens were tested in a representative high-burden setting in
Uganda (Nsambya Hospital, Kampala, Uganda), by trained staff.
DNA samples extracted fromboth isolates and specimens were
tested in parallel, and results were compared with GenoType
MTBDRplus (Hain Lifescience, Nehren, Germany) assay and
Sanger sequencing performed as described elsewhere (17).
The VerePLEX Biosystem consists of a single disposable device
comprising microfluidic PCR and microarray modules. The plat-
form includes a temperature control system (TCS) and an optical
reader (OR) which allows automatic analysis of themicroarray, pro-
vidingauser-friendlydiagnostic report (seeFig. S2 in the supplemen-
tal material) (18). The protocols for MDR-TB assay are described in
Text S3, and the primers are shown in Table S4. The assay allows
detectionofMTBCandother commonNTM, togetherwith themost
frequent mutations affecting the rpoB, katG, and inhA genes, which
are involved in phenotypic resistance to RIF and INH inMTBC.
TABLE 2 Phenotypic DST, MTBDRplus, and VerePLEX Biosystem results for the 91 MTBC clinical isolates included in the study
Phenotypic DST
resulta for:
MTBDRplus/sequencing resultb for the
following gene: VerePLEX Biosystem resultb,c for the following gene:
No. of
isolatesdRIF INH rpoB katG inhA rpoB katG inhA
R R S531L S315T1 WT S531L S315T1 WT 15
R R WT WT WT WT WT WT 1
S R WT WT WT WT WT WT 5
R R S531L WT C-15T S531L WT C-15T 16
R R S531L WT WT S531L WT WT 7
R S S531L WT WT S531L WT WT 2
R R H526D S315T1 WT H526D WT* S315T1 WT 1
R R H526D S315T1 WT WTH526D WT S315T1 WT 1
R R L511P S315N WT L511P WT* WT 1
R R H526D S315R WT H526D  313–317 WT WT 1
R R H526Y S315N WT H526Y WT* WT 1
R S D516V WT WT D516V WT WT 1
R R S531L S315T1 T-8A S531L S315T1 T-8A 2
R R L530MS531P S315T1 T-8C  530–533 WT S315T1 T-8C 1
R R S531L S315T2 WT S531L S315T2 WT 2
R R D516V S315T1 T-8A D516V S315T1 T-8A 3
R R D516V S315T1 T-8C D516V S315T1 T-8C 1
S R WT WT C-15T WT WT C-15T 11
R R D516V S315T1 WT D516V S315T1 WT 5
S R WT S315T1 WT WT S315T1 WT 5
R R H526D S315T1 WT H526D S315T1 WT 1
R R S531L S315T1 C-15T S531L S315T1 C-15T 3
R R Q513P S315T1 WT  510–513 WT S315T1 WT 1
S R WT S315N WT WT  313–317 WT WT 1
R R H526Y S315T1 C-15T H526Y S315T1 C-15T 2
S S WT WT WT WT WT WT 1
a The phenotypic drug susceptibility testing (DST) results for rifampin (RIF) and isoniazid (INH) are given as follows: R, resistant; S, sensitive.
b The results for the 91 MTBC isolates found by the MTBDRplus assay and sequencing or by the VerePLEX Biosystem are shown (wild type [WT] or mutant).
c Symbols: *, probe signal was on at the cutoff; , no WT signal.
d The number of isolates apply to all the test results.
TABLE 3 Diagnostic performance of the phenotypic DST, MTBDRplus, VerePLEX Biosystem, and Xpert MTB-RIF for detecting rifampin resistance
(rpoB) in clinical isolates and specimensa
Parameter
Value (95% CI) for clinical isolates (n 91) Value (95% CI) for clinical specimensb
Method type and no.
of indeterminate
results/total (%)MTBDRplus/seq DST
MTBDRplus/seq/Xpert
MTB-RIF (n 71) DST (n 58)
Sensitivity (%) 100.00 (94.58, 100.00) 98.53 (92.13, 99.74) 100.00 (77.19, 100.00) 100.00 (75.75, 100.00) Molecular 3/71 (4.23)
Specificity (%) 100.00 (86.2, 100.00) 100.00 (85.69, 100.00) 100.00 (93.47, 100.00) 100.00 (91.97, 100.00) Phenotypic 2/58 (3.45)
PPV (%) 100.00 (94.58, 100.00) 100.00 (94.58, 100.00) 100.00 (77.19, 100.00) 100.00 (75.75, 100.00)
NPV (%) 100.00 (86.2, 100.00) 95.83 (79.76, 99.26) 100.00 (93.47, 100.00) 100.00 (91.97, 100.00)
Negative likelihood ratio 0.00 (0.00, ?) 0.01 (0.00, 0.10) 0.00 (0.00, ?) 0.00 (0.00, ?)
Diagnostic accuracy (%) 100.00 (95.95, 100.00) 98.90 (94.03, 99.81) 100.00 (95.95, 100.00) 100.00 (93.58, 100.00)
a The diagnostic performance of the MTBDRplus assay and sequencing (MTBDRplus/seq), phenotypic drug susceptibility testing (DST), and MTBDRplus assay, sequencing, and
Xpert MTB-RIF assay (MTBDRplus/seq/Xpert MTB-RIF) for detecting rifampin resistance (rpoB) are shown. The sensitivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV), and diagnostic accuracy were calculated according to the Wilson score (www.OpenEpi.com). The positive and negative likelihood ratios were also
calculated. The lower and upper limits of the 95% confidence interval (95% CI) are shown in parentheses. The effective number of samples considered for the analysis is reported
for each target. The positive likelihood ratio cannot be computed, since specificity is always 100%.
b There were a total of 80M. tuberculosis-positive smear-positive clinical specimens and a total of 116M. tuberculosis-negative clinical specimens.
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Analysis of the diagnostic performance of the LoC assay on
clinical isolates.MTBCwas detected in all 91 clinical isolates (Ta-
ble 2). Concerning the rpoB and inhA targets, 100% concordance
was observed between the MTBDRplus and LoC assay results. In
one case, the LoC assay revealed both wild-type (WT) and mu-
tated signals from probes targeting positions 523 to 526 in rpoB,
whichwas not confirmed byMTBDRplus assay. A 95.74%concor-
dance was observed between the MTBDRplus and LoC assay re-
sults for the katG target. In two cases, probes complementary to
theWT sequence of codon 315 of katGwere detected slightly over
the on/off cutoff, but theMTBDRplus assay showed an absence of
signal from the WT probe. In another two cases, a double pattern
(mutated and WT) was detected by the LoC assay, but only the
mutation was identified by the MTBDRplus assay.
Othermutations identified by sequencing (L530M, S531P, and
Q513 in rpoB and S315N and S315R in katG) were correctly de-
tected on the chip by the absence of signal from respective WT
probes.
Compared with DST, the sensitivity and specificity of the
MTBDRplus assay for RIF were 98.53% and 100%, respectively,
and the sensitivity and specificity for INHwere 82.76% and 100%,
respectively (Tables 3, 4, and 5).
Analysis of the diagnostic performance of the LoC assay on
clinical specimens. DST results for RIF and INH were available
for 58 and 57 samples, respectively. The chips presenting incom-
plete results were repeated once and then included in the analysis
(Table 6).
Valid resultswere obtained in 99.00%, 95.80%, and95.50%of the
cases for MTBC, rpoB, katG, and inhA targets, respectively. MTBC
was detectedwith 100% sensitivity and specificity on the LoC, as well
as resistance to RIF (Tables 3, 4, and 5). One discrepant result was
detected for the katG and inhA genes, leading to a sensitivity of
93.75% and 90.91%, respectively, compared to the MTBDRplus as-
say. Overall, the sensitivity and specificity of katG and inhA targets
were 73.33% and 100%, respectively, compared to DST. Three spec-
imens gave invalid values by the LoC assay. One sample gave an in-
valid result for PCR controls, possibly due to inhibitors affecting the
reaction in the microfluidic environment. The remaining two speci-
mens also yielded invalid results with theMTBDRplus assay. All 116
MTBC culture-negative specimens were classified correctly.
In the current study, we developed and evaluated a LoC-based
assay for the diagnosis of MDR-TB. LoC devices represent prom-
ising tools to fill the diagnostic gap in low-income countries: they
integratemany of the laboratory components on a small chip, thus
reducing infrastructure and technical requirements but preserv-
ing analytical capabilities. In addition, the operating speed, ease of
modification (addition/removal of probes), and ability to perform
multiplex tests and to scale down costs represent other relevant
features of LoCs (19, 20).
Our results showed high specificity and sensitivity of the semiau-
tomatedVerePLEXBiosystem for theMDR-TB targets, thus suggest-
ing an usefulness of the platform for fast and simple diagnosis of
MDR cases in centralized laboratories. The sensitivity and specificity
of theNTMprobeson the sameplatformwere evaluatedbyLazzeri et
al. (21). The assay allowed us to identify correctlyMTBC in 100% of
the smear-positive samples tested independently of the smear mi-
croscopy score, with a small number of indeterminate results due
most likely to the lowqualityofDNAextracted.Resistance toRIFand
INH was detected by the chip with high sensitivity and specificity in
agreement with the minimal requirements established by the WHO T
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for molecular tools, comparable to the sensitivity and specificity of
the MTBDRplus assay (12). The limit of detection of the assay was
observed in the range of 101 genome copies/reaction, as reported in
Table S5 in the supplemental material.
A separate array layout for spoligotyping of MTBC was also
developed in the TM-REST Project (data not shown). The possi-
bility of integrating the probes for spoligotyping, MDR- and ex-
tensively DR-TB in one medium-density microarray layout by
using separate multiplex-PCR would enhance the benefits of the
microarray assays and would enable the reduction of time to re-
sults compared to other available tests (22–24).
The ease of customization of the array design makes the LoC a
versatile tool for easy integration of relevant targets for local ge-
netic variants, new genes and/or mutations, and novel key drugs
included in new therapeutic regimens. In addition, the LoC can be
adapted for other diagnostic or research needs, thus providing a
TABLE 5 Diagnostic performance of the phenotypic DST, MTBDRplus, and VerePLEX Biosystem for detecting M. tuberculosis in clinical isolates
and specimensa
Parameter
Value (95% CI) for clinical isolates (n 91)
Value (95% CI) for clinical
specimens (n 196)b by
MTBDRplus/seq/Xpert
MTB-RIF
No. of indeterminate
results/total (%)MTBDRplus/seq DST
Sensitivity (%) 100.00 (95.95, 100.00) 100.00 (95.95, 100.00) 100.00 (95.31, 100.00) 2/196 (1.02)
Specificity (%) Undefined Undefined 100.00 (96.79, 100.00)
PPV (%) 100.00 (95.95, 100.00) 100.00 (95.95, 100.00) 100.00 (95.31, 100.00)
NPV (%) Undefined Undefined 100.00 (96.79, 100.00)
Negative likelihood ratio Undefined Undefined 0.00
Diagnostic accuracy (%) Undefined Undefined 100.00 (98.06, 100.00)
a The diagnostic performance of the MTBDRplus/seq assays, phenotypic drug susceptibility testing (DST), and MTBDRplus/seq/Xpert MTB-RIF assays for detectingM. tuberculosis
are shown. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), and diagnostic accuracy were calculated according to the Wilson score
(www.OpenEpi.com). The positive and negative likelihood ratios were also calculated. The lower and upper limits of the 95% confidence interval (95% CI) are shown in parenthe-
ses. The effective number of samples considered for the analysis is reported for each target. The positive likelihood ratio cannot be computed, since specificity is always 100%.
b There were a total of 80M. tuberculosis-positive smear-positive clinical specimens and a total of 116M. tuberculosis-negative clinical specimens.
TABLE 6 Phenotypic DST, MTBDRplus, Xpert MTB-RIF, and VerePLEX Biosystem M. tuberculosis results for the 80 smear-positive MTBC culture-
positive clinical specimens included in the study
Phenotypic
DST resulta
for: MTBDRplus/sequencing resultb for the following gene:
Xpert
MTB-RIF
resultc for: VerePLEX MTB resultb,d for the following gene:
No. of
clinical
specimenseRIF INH rpoB katG inhA MTB RIF rpoB katG inhA
S R WT WT C-15T WT WT C-15T 9
R R S531L S315T1 WT S531L S315T1 WT 2
R R S531L WT S315T1 WT S531L WT S315T1 WT 1
S R WT WT WT WT WT WT 6
R R D516V S315T1 WT D516V S315T1 WT 2
R R S531L WT WT S531L WT WT 2
S R WT S315T1 WT WT S315T1 WT 4
R R S531L S315T1/T2 WT S531L S315T1/T2 WT 1
R R Q513P S315T1 WT  510–513 WT S315T1 WT 1
S R WT S315N WT WT  313–317 WT WT 1
R S S531L WT WT S531L WT WT 1
R R S531L WT C-15T S531L  313–317 WT WT 1
S S WT WT WT WT WT WT 15
R R  518–525 WT,  530–533 WT S315T1 WT  523–526 WT, S531L S315T1 WT 1
D516V S315T1 T-8C D516V S315T1 T-8C 1
WT WT WT WT WT WT 15
WT S315T1 WT WT S315T1 WT 1
S S WT WT WT 9
pos WT WT WT WT 4
WT WT WT PCNV PCNV PCNV 1
S S ND S315T1 WT MTBND MTBND MTBND 1
S S ND WT WT ND ND ND 1
a The phenotypic drug susceptibility testing results for rifampin and isoniazid are given as follows: R, resistant; S, sensitive.
b The results for the 80 smear-positive, MTBC culture-positive isolates found by the MTBDRplus assay and sequencing or by the VerePLEX Biosystem are shown (wild type [WT]
or mutant). , no WT signal; ND, not detected.
c MTB,M. tuberculosis; pos, positive.
d PCNV, PCR controls not valid; MTBND,M. tuberculosis not detected; ND, not detected.
e The number of smear-positive, MTBC culture-positive clinical specimens applies to all the tests.
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multipurpose platform suitable for other relevant diseases (e.g.,
influenza, malaria, tropical diseases) (25, 26).
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